In this issue of The Lancet Infectious Diseases, Daniel Jenkin and colleagues reported the results of a phase 1 study of a new ChAdOx1 vector vaccine against Rift Valley fever (RVF).
RVF is a viral zoonosis that primarily affects animals but can infect humans.
The development of an effective human vaccine against RVF that elicits a long-term immune response is of enormous clinical importance, wrote these researchers on April 12, 2023.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
